Shares of bluebird bio Inc (NASDAQ:BLUE) surged 50% on Wednesday after the gene therapy developer announced an amended acquisition agreement with private equity firms Carlyle and SK Capital, offering shareholders a higher upfront cash payout. The revised deal includes a $5 per share cash offer, replacing a previous bid that had offered $3 per share upfront and a contingent value right (CVR) of $6.84 per share, payable if certain sales milestones were met.
Although the revenue and EPS for Carlyle (CG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CG's first-quarter results reflect increases in revenues and the AUM balance. Expenses also decline year over year.
The Carlyle Group, Inc. (NASDAQ:CG ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Daniel Harris - Partner & Head, Public Investor Relations Harvey Schwartz - CEO & Director John Redett - CFO & Head, Corporate Strategy Conference Call Participants Ben Budish - Barclays Alex Blostein - Goldman Sachs Patrick Davitt - Autonomous Research Brian Bedell - Deutsche Bank Brian McKenna - Citizens Ken Worthington - JPMorgan Mike Brown - Wells Fargo Michael Cyprys - Morgan Stanley Bill Katz - TD Cowen Kyle Voigt - KBW Operator Good day, and thank you for standing by. Welcome to The Carlyle Group First Quarter 2025 Earnings Conference Call.
U.S. private equity group Carlyle Group has sold its entire 10.44% stake in India's PNB Housing Finance via block deals, business news website Moneycontrol reported on Thursday, citing a termsheet.
Carlyle Group CEO Harvey Schwartz warned that a recession is a possibility. But he told Bloomberg Television it was too early to make a judgment, and there could be a rebound.
Carlyle (CG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CGBD is a defensively structured BDC with a strong portfolio, solid dividend coverage, and increasing investor recognition, currently trading at a ~0.96x P/BV multiple. The merger with CSL III will enhance CGBD's defensive nature, increasing assets to $2.8B and improving metrics. Post-merger, CGBD will have better diversification, higher first-lien debt exposure, and lower non-accruals.
CGBD's merger with Carlyle Secured Lending and CSL III signifies a strategic alignment that is likely to enhance operational efficiency and minimize costs.
Energean PLC (LSE:ENOG) has confirmed the termination of its proposed sale of assets in Egypt, Italy and Croatia to Carlyle International Energy Partners. The company said the decision followed the failure to obtain regulatory approvals in Italy and Egypt by the agreed longstop date of 20 March 2025.
UK-based Energean said on Friday it was terminating its deal with private equity fund Carlyle for some of the gas producer's assets due to pending regulatory approvals in Italy and Egypt.
Private equity group Carlyle is seeking a buyer for its Colombian oil producer SierraCol for around $1.5 billion, according to people with knowledge of the matter.